S&P 500 (NYSE:SPY) component Allergan, Inc. (NYSE:AGN) will unveil its latest earnings on Wednesday, August 3, 2011. Allergan, Inc. is a global specialty health care company. It discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices, as well as over-the-counter products.
Allergan, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for profit of 95 cents per share, a rise of 11.8% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 92 cents. For the year, analysts are projecting net income of $3.64 per share, a rise of 15.2% from last year.
Past Earnings Performance: The company topped estimates last quarter after missing forecasts the quarter prior. In the first quarter, it reported profit of 77 cents per share against a mean estimate of net income of 74 cents per share. In the fourth quarter of the last fiscal year, it missed forecasts by one cent.
Wall St. Revenue Expectations: On average, analysts predict $1.34 billion in revenue this quarter, a rise of 7.2% from the year ago quarter. Analysts are forecasting total revenue of $5.31 billion for the year, a rise of 8.8% from last year’s revenue of $4.88 billion.
Analyst Ratings: 14 out of 22 analysts surveyed (63.6%) have a buy rating on Allergan.. This is below the mean analyst rating of 10 competitors, which average 72.5% buy ratings.
Revenue has risen the past four quarters. Revenue increased 10.1% to $1.27 billion in first quarter. The figure rose 6.9% in the fourth quarter of the last fiscal year from the year earlier, climbed 5.9% in the third quarter of the last fiscal year from the year-ago quarter and 10.3% in the second quarter of the last fiscal year.
Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH), ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA), Endo Pharmaceuticals (NASDAQ:ENDP), Medicis Pharmaceutical Corp. (NYSE:MRX), Akorn, Inc. (NASDAQ:AKRX), Novartis AG (NYSE:NVS), GlaxoSmithKline plc (NYSE:GSK), Merck & Co., Inc. (NYSE:MRK), and Hospira, Inc. (NYSE:HSP).
Stock Price Performance: During May 3, 2011 to July 28, 2011, the stock price had risen $2.82 (3.6%) from $78.93 to $81.75. The stock price saw one of its best stretches over the last year between March 31, 2011 and April 11, 2011 when shares rose for eight-straight days, rising 5.9% (+$4.19) over that span. It saw one of its worst periods between July 21, 2011 and July 27, 2011 when shares fell for five-straight days, falling 4.3% (-$3.61) over that span. Shares are up $13.17 (+19.2%) year to date.
(Source: Xignite Financials)